Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19)

BACKGROUND: Anthracycline (A) or taxane T-based regimens are the standard early-line chemotherapy for metastatic breast cancer (BC). A previous study has shown a survival benefit of eribulin in heavily pretreated advanced/recurrent BC patients. The present study aimed to compare the benefit of eribu...

Descripción completa

Detalles Bibliográficos
Autores principales: Aogi, Kenjiro, Watanabe, Kenichi, Kitada, Masahiro, Sangai, Takafumi, Ohtani, Shoichiro, Aruga, Tomoyuki, Kawaguchi, Hidetoshi, Fujisawa, Tomomi, Maeda, Shigeto, Morimoto, Takashi, Sato, Nobuaki, Takao, Shintaro, Morita, Satoshi, Masuda, Norikazu, Toi, Masakazu, Ohno, Shinji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213561/
https://www.ncbi.nlm.nih.gov/pubmed/33891194
http://dx.doi.org/10.1007/s10147-021-01920-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213561/
https://www.ncbi.nlm.nih.gov/pubmed/33891194
http://dx.doi.org/10.1007/s10147-021-01920-0

Ejemplares similares